|
1.
|
総説
|
De-escalation of perioperative systemic therapy for early breast cancer. 2026/08
|
|
2.
|
原著
|
Germline pathogenic variants in Japanese adolescents and young adults with advanced solid tumors: a nationwide tumor-normal paired sequencing study. 2026/07
|
|
3.
|
原著
|
Tumor Lineage–Specific Disparities in Access to Genome-Matched Therapies Among Adolescents and Young Adults in Japan: A Nationwide Genomic Profiling Study 2026/07
|
|
4.
|
原著
|
Efficacy and prognostic predictors of primary systemic therapy for de novo Stage IV breast cancer. Exploratory analysis of JCOG1017 PRIM-BC. 2026/03
|
|
5.
|
症例報告
|
NTRK-rearranged soft tissue sarcoma that originated from the head and neck with a robust response to the TRK inhibitor larotrectinib. 2026/01
|
|
6.
|
症例報告
|
Sporadic medullary thyroid carcinoma with a rare RET transmembrane domain (A641R) mutation that respond to selpercatinib: a case report with review of literature 2025/07/10
|
|
7.
|
原著
|
Phase I study of H3B-6545 in patients with estrogen receptor-positive breast cancer 2025/06/13
|
|
8.
|
原著
|
Appearance-related needs and challenges among cancer patients undergoing systemic therapy: a comprehensive survey study. 2025/03
|
|
9.
|
原著
|
Prognostic Impact of Stimulator of Interferon Genes Expression in Triple Negative Breast Cancer 2025/02
|
|
10.
|
原著
|
Barriers to career development and gender-related challenges in oncology: the results of the JSMO and JSCO surveys in Japan 2025
|
|
11.
|
原著
|
Clinical potential of antibody–drug conjugates in early-phase clinical trials for late-line treatment of advanced solid tumors 2025
|
|
12.
|
原著
|
Enfortumab vedotin in patients with previously treated advanced breast cancer in the Phase 2 EV-202 study 2025
|
|
13.
|
原著
|
Gemcitabine-based chemotherapy for advanced soft tissue sarcoma: identifying the appropriate dose and schedule 2024/12/21
|
|
14.
|
症例報告
|
Confirmatory diagnosis and successive chemotherapeutic treatments of metastatic skeletal EWSR1::NFATC2 sarcoma: A case report 2024/12/20
|
|
15.
|
原著
|
Addressing the knowledge gap in the genomic landscape and tailored therapeutic approaches to adolescent and young adult cancers. 2024/08
|
|
16.
|
原著
|
Outcomes in nonmetastatic hormone receptor-positive HER2-negative pure mucinous breast cancer: A multicenter cohort study 2024/05/14
|
|
17.
|
原著
|
Clinical impact of proteinuria on renal function and treatment outcomes in patients with radioiodine-refractory thyroid cancer treated with lenvatinib 2024/04/30
|
|
18.
|
原著
|
Assessment of pazopanib-related heart failure in patients with advanced soft tissue sarcoma - A single institute analysis 2024/01/25
|
|
19.
|
症例報告
|
Primary ovarian insufficiency associated with lenvatinib therapy in a patient with hepatocellular carcinoma: A case report 2023/08/31
|
|
20.
|
原著
|
First-in-human study of E7130 (a tumor microenvironment-ameliorating microtubule inhibitor) in patients with advanced solid tumors: Primary results of the dose-escalation part 2023/08/01
|
|
21.
|
原著
|
The Geriatric Nutritional Risk Index as a prognostic factor in older adult patients with locally advanced head and neck cancer receiving definitive chemoradiotherapy with tri-weekly cisplatin 2023/06
|
|
22.
|
原著
|
Clinical characteristics of sarcoma cases in which long-term disease control was achieved with trabectedin treatment: A retrospective study 2023/03/01
|
|
23.
|
原著
|
Comparison of Paclitaxel plus Carboplatin versus Observation in Patients with Recurrent or Metastatic Adenoid Cystic Carcinoma of the Head and Neck 2023
|
|
24.
|
症例報告
|
Myocarditis associated with immune-checkpoint inhibitors diagnosed by cardiac magnetic resonance imaging 2022/12/13
|
|
25.
|
原著
|
Clinical significance of the neutrophil-to-lymphocyte ratio in oligometastatic breast cancer 2022/11
|
|
26.
|
原著
|
Disparities in Access to Systemic Treatment for Breast Cancer in Thailand and Major Asian Territories 2022/06
|
|
27.
|
原著
|
Phase 1 study of the liposomal formulation of eribulin (E7389-LF): Results from the breast cancer expansion cohort 2022/06
|
|
28.
|
原著
|
Serial circulating tumor DNA monitoring of CDK4/6 inhibitors response in metastatic breast cancer 2022/05
|
|
29.
|
原著
|
A proposed clinical scoring system for initiation of lenvatinib treatment in radioiodine-refractory thyroid cancer patients 2022/04
|
|
30.
|
原著
|
HER2 expression, copy number variation and survival outcomes in HER2-low non-metastatic breast cancer: an international multicentre cohort study and TCGA-METABRIC analysis 2022/03/17
|
|
31.
|
原著
|
Post-systemic chemotherapy prognoses of recurrent/metastatic soft tissue sarcoma patients with retroperitoneal/intra-abdominal origin versus those with extremities/trunk origin 2022
|
|
32.
|
原著
|
妊孕性温存に関するがん研究会有明病院医療従事者の意識調査と当院の現状 2022
|
|
33.
|
症例報告
|
Chilblain lupus-like cutaneous reaction associated with systemic lupus erythematosus induced by immune checkpoint inhibitor 2021/12/24
|
|
34.
|
原著
|
Pre-Treatment Neutrophil-to-Lymphocyte Ratio (NLR) as a Predictive Marker of Pazopanib Treatment for Soft-Tissue Sarcoma 2021/12/14
|
|
35.
|
原著
|
Clinical impact of cachexia in head and neck cancer patients who received chemoradiotherapy 2021/11/08
|
|
36.
|
原著
|
Clinicopathological and genomic features in patients with head and neck neuroendocrine carcinoma 2021/11
|
|
37.
|
原著
|
A phase I study of combined trabectedin and pegylated liposomal doxorubicin therapy for advanced relapsed ovarian cancer 2021/10/26
|
|
38.
|
原著
|
A first-in-human, phase 1 study of the NEDD8 activating enzyme E1 inhibitor TAS4464 in patients with advanced solid tumors 2021/08
|
|
39.
|
原著
|
Tumor growth rate as a prognostic factor for metastatic or recurrent adenoid cystic carcinoma of the head and neck patients treated with carboplatin plus paclitaxel 2021/08
|
|
40.
|
原著
|
Changes in Neutrophil-to-lymphocyte Ratio Predict Efficacy of Trabectedin for Soft-tissue Sarcoma 2021/07/03
|
|
41.
|
原著
|
Clinical features and outcomes of metastatic pheochromocytoma treated by cytotoxic chemotherapy 2021/06/28
|
|
42.
|
原著
|
Prognostic significance of 8 weeks' relative dose intensity of lenvatinib in treatment of radioiodine-refractory differentiated thyroid cancer patients 2021/06/28
|
|
43.
|
原著
|
Japanese single-institution analysis of mitotane for patients with adrenocortical carcinoma 2021/06/26
|
|
44.
|
症例報告
|
Case Report: A Case of Trimethoprim/Sulfamethoxazole-Triggered Hypotensive Shock: Cytokine Release Syndrome Related to Immune Checkpoint Inhibitors and Drug-Induced Hypersensitivity Syndrome 2021/04
|
|
45.
|
原著
|
Comparison of the efficacy and safety of the EXTREME regimen for treating recurrent or metastatic head and neck squamous cell carcinoma in older and younger adult patients 2021/04
|
|
46.
|
原著
|
Efficacy of Paclitaxel-based Chemotherapy After Progression on Nivolumab for Head and Neck Cancer 2021/03/04
|
|
47.
|
原著
|
Baseline Tumour Size as a Prognostic Factor for Radioiodine-refractory Differentiated Thyroid Cancer Treated With Lenvatinib 2021/03
|
|
48.
|
原著
|
Differences in the efficacy and safety of eribulin in patients with soft tissue sarcoma by histological subtype and treatment line 2021/01
|
|
49.
|
原著
|
Pre-treatment Neutrophil-to-Lymphocyte Ratio Predicts Efficacy of Eribulin for Soft-tissue Sarcoma 2021/01
|
|
50.
|
原著
|
Tumor growth rate as a prognostic factor for metastatic or recurrent adenoid cystic carcinoma of the head and neck patients treated with carboplatin plus paclitaxel 2020/11/21
|
|
51.
|
症例報告
|
An extragonadal germ cell tumor with dermatomyositis: A case report and literature review 2020/11
|
|
52.
|
原著
|
Neutrophil-to-Lymphocyte Ratio as a Prognostic Marker for Anaplastic Thyroid Cancer Treated With Lenvatinib 2020/09
|
|
53.
|
原著
|
Efficacy of Nivolumab for Head and Neck Cancer Patients with Primary Sites and Histological Subtypes Excluded from the CheckMate-141 Trial 2020/06
|
|
54.
|
原著
|
Long Non-coding NR2F1-AS1 is Associated with Tumor Recurrence in Estrogen Receptor-positive breast cancers 2020/05/11
|
|
55.
|
原著
|
Prognostic impact of ACTN4 gene copy number alteration in hormone receptor-positive, HER2-negative, node-negative invasive breast carcinoma 2020/04/08
|
|
56.
|
原著
|
Clinical significance of gene mutation in ctDNA analysis for hormone receptor-positive metastatic breast cancer 2020/04
|
|
57.
|
原著
|
Sequential Analysis of Neutrophil-to-lymphocyte Ratio for Differentiated Thyroid Cancer Patients Treated With Lenvatinib 2020/03
|
|
58.
|
原著
|
Retrospective Analysis of Trabectedin Therapy for Soft Tissue Sarcoma 2019/09
|
|
59.
|
原著
|
Outcome for Advanced or Metastatic Soft Tissue Sarcoma of Nonextremities Treated with Doxorubicin-Based Chemotherapy: A Retrospective Study from a Single Cancer Institution 2018/04/18
|
|
60.
|
原著
|
Tumour-infiltrating lymphocytes are correlated with higher expression levels of PD-1 and PD-L1 in early breast cancer 2017/05/02
|
|
61.
|
原著
|
Prognostic Significance of Progesterone Receptor Expression in Estrogen-Receptor Positive, HER2-Negative, Node-Negative Invasive Breast Cancer with a Low Ki-67 Labeling Index 2017/02
|
|
62.
|
原著
|
A novel combination of serum microRNAs for detecting breast cancer in the early stage 2016/03
|
|
63.
|
原著
|
Loss of microRNA-27b contributes to breast cancer stem cell generation by activating ENPP1 2015/06/12
|
|
64.
|
原著
|
The expression and clinical significance of ribophorin II (RPN2) in human breast cancer 2015/06
|
|
65.
|
原著
|
Brain metastatic cancer cells release microRNA-181c-containing extracellular vesicles capable of destructing blood-brain barrier 2015/04
|
|
66.
|
原著
|
Prognostic impact of Ki-67 labeling indices with 3 different cutoff values, histological grade, and nuclear grade in hormone-receptor-positive, HER2-negative, node-negative invasive breast cancers 2015/03
|
|
67.
|
原著
|
Exosomes from bone marrow mesenchymal stem cells contain a microRNA that promotes dormancy in metastatic breast cancer cells 2014/07
|
|
68.
|
総説
|
Exosome in disease biology, diagnosis, and therapy 2014
|
|
69.
|
総説
|
Exosomal tumor-suppressive microRNAs as novel cancer therapy: "exocure" is another choice for cancer treatment 2013/03
|
|
70.
|
総説
|
Role of microRNA in cancer development: biology and clinical applications がん発生におけるマイクロRNAの役割: 生物学と臨床応用 2012/03
|
|
71.
|
原著
|
Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer 2012
|
|
72.
|
原著
|
A retrospective study of the impact of age on patterns of care for elderly patients with metastatic breast cancer 2011
|
|
73.
|
総説
|
Cancer Stem Cells in Breast Cancer 2011
|
|
74.
|
原著
|
Second-line chemotherapy in patients with primary unknown cancer 2011
|
|
75.
|
原著
|
Disruption of the blood brain barrier by brain metastases of triple-negative and basal-type breast cancer but not HER2/neu-positive breast cancer 2010
|
|
76.
|
原著
|
Immunohistochemical expression of HER1, HER3, and HER4 in HER2-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy 2010
|
|
77.
|
原著
|
Influence of suboptimal treatment in patients with mediastinal primary nonseminomatous germ cell tumors 2010
|
|
78.
|
原著
|
Brain metastases in patients who receive trastuzumab-containing chemotherapy for HER2-overexpressing metastatic breast cancer 2009
|
|
79.
|
原著
|
Immunohistochemical expression of PTEN and phosphorylated Akt are not correlated with clinical outcome in breast cancer patients treated with trastuzumab-containing neo-adjuvant chemotherapy 2009
|
|
80.
|
症例報告
|
Relapse with malignant transformation after chemotherapy for primary mediastinal seminoma 2009
|
|
81.
|
総説
|
乳がん標準薬物療法（経口剤） 2009
|
|
82.
|
原著
|
Combination chemotherapy with cisplatin and irinotecan in patients with adenocarcinoma of the small intestine 2008
|
|
83.
|
原著
|
Immunohistochemical profiles of brain metastases from breast cancer 2008
|
|
84.
|
症例報告
|
Nocardia exalbida brain abscess in a patient with follicular lymphoma 2008
|
|
85.
|
症例報告
|
Therapy-related acute promyelocytic leukemia caused by hormonal therapy and radiation in a patient with recurrent breast cancer 2008
|
|
86.
|
総説
|
Surgery for advanced breast cancer from the viewpoint of medical oncologist 腫瘍内科医の観点から進行乳がんの手術 2007/06
|
|
87.
|
症例報告
|
MRCP and ERCP in Lemmel syndrome 2005
|
|
88.
|
総説
|
Combination chemotherapy for gastric cancer including LV/5-FU, LV / 5-FUを含む胃癌の併用化学療法 2004/11
|
|
5件表示
|
|
全件表示(88件)
|
